Genomic Health Continues Its Profitable Ways
The cancer test maker is growing earnings much faster than revenue.
Genomic Health
GHDX
$71.09
$0.41
0.6%
BATS BZX Real Time Price as of March 26, 2019, 10:33 a.m.
View Interactive GHDX Charts
Genomic Health's diagnostic tests offer innovative cancer screening.
News & Analysis: Genomic Health
The Fool has written over 100 articles on Genomic Health.
All
Market Moves
Earnings
Genomic Health, Inc. (GHDX) Q4 2018 Earnings Conference Call Transcript
GHDX earnings call for the period ending December 31, 2018.
Here's Why Genetic Testing Stocks Rose as Much as 31.8% in January
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
3 High-Growth Stocks That Are Just Getting Started
Inject a little above-average wealth-building potential into your portfolio with any -- or all -- of these three stocks.
This High-Growth Biotech Industry Is as Competitive as Ever Heading Into 2019
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
Genomic Health Starts Sprinting
Record revenue and profits lead management to increase 2018 guidance.
Here's Why Genomic Health Popped as Much as 30.2% Today
The genetic-testing leader kept up its impressive streak of profitable growth during the third quarter of 2018. It now expects earnings several times higher than previous estimates.
Genomic Health Inc (GHDX) Q3 2018 Earnings Conference Call Transcript
GHDX earnings call for the period ending September 30, 2018.
Here's Why Genomic Health, Inc. Gained 14.8% in September
The genetic testing leader's year-to-date momentum continued for yet another month. Should investors be concerned by the streak's abrupt end in October?
Genomic Health Starts Its Marathon
The CEO sees steady growth as the company increases volume of its cancer tests and improves reimbursement from payers.
